Skip to main content

People in the News: Thomas Bachmann, Joseph Eggler, and More


Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group. He will be responsible for two divisions: the Magnetic Resonance Spectroscopy division, which includes NMR, electron paramagnetic resonance, and compact magnetic resonance, and the Preclinical Imaging division, which includes MRI, magnetic particle imaging, X-ray micro-CT, and optical and PET/SPECT/CT molecular imaging.

Bachmann was CEO of Tecan for seven years, and for two years before that he was CEO of the Arbonia-Forster Group’s Steel Systems business.

Provista Diagnostics said this week that Joseph Eggler has joined the company as chief commercial officer. In the job, he will execute and manage the company’s sales efforts, as well as commercial aspects of the business.

Eggler previously was at Prometheus Laboratories, where he spent 12 years, and he has over two decades of experience in planning, sales and marketing development, and in identifying and creating key relationships, Provista said.

Peter Hirth has joined KineMed's board of directors. Hirth was previously CEO of Plexxikon. Before that he was president of Sugen and vice president of research at Boehringer Mannheim.

Applied Proteomics has appointed Genting Berhad Chairman and CEO Tan Sri Lim Kok Thay to its board of directors upon completion of a Series C funding round led by Genting Berhad (see story this issue).

The Scan

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.